REGMF (RemeGen Co) FCF Margin % : -130.88% (As of Jun. 2024)

View and export this data going back to 2020. Start your Free Trial

What is RemeGen Co FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. RemeGen Co's Free Cash Flow for the six months ended in Jun. 2024 was $-133.4 Mil. RemeGen Co's Revenue for the six months ended in Jun. 2024 was $102.0 Mil. Therefore, RemeGen Co's FCF Margin % for the quarter that ended in Jun. 2024 was -130.88%.

As of today, RemeGen Co's current FCF Yield % is -10.87%.

The historical rank and industry rank for RemeGen Co's FCF Margin % or its related term are showing as below:

REGMF' s FCF Margin % Range Over the Past 10 Years
Min: -1870.4 Med: -241.03 Max: -24.84
Current: -128.09

During the past 7 years, the highest FCF Margin % of RemeGen Co was -24.84%. The lowest was -1870.40%. And the median was -241.03%.

REGMF's FCF Margin % is ranked better than
50% of 1012 companies
in the Biotechnology industry
Industry Median: -129.705 vs REGMF: -128.09

RemeGen Co FCF Margin % Historical Data

The historical data trend for RemeGen Co's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RemeGen Co FCF Margin % Chart

RemeGen Co Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

FCF Margin %

Get a 7-Day Free Trial

-24.84

-263.26

-218.80

RemeGen Co Semi-Annual Data
	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
FCF Margin %	Get a 7-Day Free Trial								-223.05	-275.80	-182.44	-130.88	-

Competitive Comparison of RemeGen Co's FCF Margin %

For the Biotechnology subindustry, RemeGen Co's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

RemeGen Co's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, RemeGen Co's FCF Margin % distribution charts can be found below:

* The bar in red indicates where RemeGen Co's FCF Margin % falls into.

Save Embed

;

Save Embed

;

RemeGen Co FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

RemeGen Co's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-329.762	/	150.714
	=	-218.80 %

RemeGen Co's FCF Margin for the quarter that ended in Jun. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Jun. 2024 )	/	Revenue (Q: Jun. 2024 )
	=	-133.442	/	101.955
	=	-130.88 %

RemeGen Co FCF Margin % Related Terms

Thank you for viewing the detailed overview of RemeGen Co's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

RemeGen Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » RemeGen Co Ltd (OTCPK:REGMF) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

09995:Hong Kong REG:Germany 688331:China

Address

58 Middle Beijing Road, Yantai Area of Shandong Pilot Free Trade Zone, Yantai Development Zone, Yantai, CHN

Website

https://www.remegen.com

RemeGen Co Ltd is a China-based company mainly engaged in the research, development and manufacture of innovative biopharmaceuticals. The company offers Telitacicept (RC18) for use in the treatment of systemic lupus erythematosus an autoimmune disease and Disitamab Vedotin (RC48) for use in the treatment of various cancers. The company's products are mainly used to treat major diseases such as autoimmune diseases, oncology, and ophthalmology. The company has its operations in China and the USA and derives the majority of its revenue from China.